«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年04期

页码:

590-594

栏目:

出版日期:

2024-08-25

文章信息/Info

Title:

Effects of alpha-interferon on Th1/Th2 and lung function in the treatment of acute respiratory virus infection

作者:

陈冬丽¹; 邓迎丽²; 毕 婧³

725000 陕西,安康市中心医院北院急诊医学科¹、呼吸二科²、呼吸一科³

Author(s):

Chen Dongli¹;  Deng Yingli²;  Bi Jing³.

¹Department of emergency medicine; ²First department of respiratory; ³Second department of respiratory, North Hospital of Ankang Central Hospital, Ankang 725000, China

关键词:

急性呼吸道病毒感染;  α-干扰素;  辅助性T细胞;  肺功能

Keywords:

Acute respiratory virus infection;  α- interferon;  Helper T cells;  Pulmonary function

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2024.04.016

摘要:

目的 分析α-干扰素治疗急性呼吸道病毒感染的疗效及其对辅助性T细胞1(T helper cell 1, Th1)/辅助性T细胞2(T helper cell 2, Th2)平衡及肺功能的影响。方法 选择2020年12月至2022年12月我院收治的急性呼吸道病毒感染患者79例,分为观察组35例和对照组44例。两组均给予常规对症治疗,对照组采用利巴韦林注射液雾化吸入,观察组采用重组人干扰素α-2b注射液雾化吸入。比较两组临床疗效、治疗后临床症状消失时间; 检测治疗前后肺功能指标[用力肺活量(forced vital capacity, FVC)、第一秒用力呼气容积(forced expiratory volume in the first second, FEV₁)、呼气流量峰值(peak expiratory flow, PEF)],检测Th1、Th2细胞比例并计算Th1/Th2值,检测血清C反应蛋白(C-reactive protein, CRP)、白细胞介素(interleukin-6, IL-6)、肿瘤坏死因子-α(tumor necrosis factor were detected- α, TNF-α)水平。结果 观察组治疗总有效31例(88.57%),高于对照组30例(68.18%)(P<0.05); 治疗后观察组咽喉疼痛、咳嗽、流涕、退热消失时间为(80.43±11.35)h、(65.28±15.63)h、(35.52±11.24)h、(34.32±8.64)h短于对照组(92.64±15.49)h、(80.47±11.28)h、(57.26±13.44)h、(51.37±10.12)h(P<0.05); 观察组治疗后FVC(1.35±0.24)L、FEV₁(2.47±0.42)L、PEF(195.32±30.12)L/min高于对照组(1.22±0.18)L、(2.06±0.39)L、(177.58±28.42)L/min(P<0.05); 治疗后观察组Th1(11.24±2.08)%、Th1/Th2(1.77±0.53)%高于对照组(9.36±1.55)%、1.35±0.42,观察组Th2(6.33±0.87)%低于对照组(6.92±1.13)%(P<0.05); 观察组CRP(8.63±1.95)mg/L、IL-6(34.26±6.51)pg/ml、TNF-α(118.62±9.17)pg/ml低于对照组(14.25±3.76)mg/L、(51.22±9.06)pg/ml、(146.02±11.64)pg/ml(P<0.05)。结论 α-干扰素治疗急性呼吸道病毒感染疗效好,有利于促进Th1/Th2细胞平衡,降低CRP、IL-6、TNF-α水平,促进患者肺功能恢复具有临床意义。

Abstract:

Objective To analyze the efficacy of α-interferon in the treatment of acute respiratory virus infection and its effects on T helper cell 1(Th1)/T helper cell 2(Th2)and lung function. Methods A total of 79 patients with acute respiratory virus infection admitted to North Hospital of Ankang Central Hospital from December 2020 to December 2022 were divided into observation group 35 cases and control group 44 cases using random number table method. Both groups were given routine symptomatic treatment, the control group received nebulized inhalation of ribavirin injection, and the observation group received recombinant human interferon α-2b injection nebulized inhalation. Compare the clinical efficacy and time of symptom disappearance after treatment between the two groups; The pulmonary function indexes [forced vital capacity(FVC), forced expiratory volume in the first second(FEV₁), peak expiratory flow(PEF)] before and after treatment were detected, the proportion of Th1 and Th2 cells was detected, and the Th1/Th2 value was calculated. Serum C-reactive protein(CRP), interleukin(IL-6), and tumor necrosis factor were detected-α(TNF-α)Horizontal. Results The total effective rate of the observation group was 31 cases(88.57%), significantly higher than that of the control group 30 cases(68.18%)(P<0.05); After treatment, the disappearance time of throat pain, cough, runny nose, and fever in the observation group was(80.43±11.35)h,(65.28±15.63)h,(35.52±11.24)h, and(34.32±8.64)h, respectively, which were significantly shorter than those in the control group [92.64±15.49)h,(80.47±11.28)h,(57.26±13.44)h, and(51.37±10.12)h, respectively, P<0.05]; After treatment, the FVC, FEV₁, and PEF in the observation group were(1.35±0.24)L,(2.47±0.42)L, and(195.32±30.12)L/min, respectively, which were significantly higher than those in the control group [1.22±0.18)L,(2.06±0.39)L, and(177.58±28.42)L/min, respectively, P<0.05]; After treatment, the Th1 and Th1/Th2 values in the observation group were(11.24±2.08)% and(1.77±0.53)%, respectively, significantly higher than those in the control group(9.36±1.55)% and(1.35±0.42)%, respectively). The Th2 values in the observation group were(6.33±0.87)%, lower than those in the control group(6.92±1.13)%(P<0.05); Post treatment observation group CRP, IL-6, TNF- α The levels were(8.63±1.95)mg/L,(34.26±6.51)pg/ml, and(118.62±9.17)pg/ml, respectively, which were significantly lower than those in the control group [(14.25±3.76)mg/L,(51.22±9.06)pg/ml,(146.02±11.64)pg/ml, P<0.05]. Conclusion α- Interferon has a good therapeutic effect on acute respiratory virus infection, which is beneficial for promoting Th1/Th2 cell balance and reducing CRP, IL-6, and TNF- α Level, can promote the recovery of lung function in patients, with high safety.

参考文献/References:

1 Wang Y, Eccles R, Bell J, et al. Management of acute upper respiratory tract infection: the role of early intervention[J]. Expert Rev Respir Med, 2021, 15(12): 1517-1523.
2 Rosas-Salazar C, Tang ZZ, Shilts MH, et al. Upper respiratory tract bacterial-immune interactions during respiratory syncytial virus infection in infancy[J]. J Allergy Clin Immunol, 2022, 149(3): 966-976.
3 Li YT, Liang Y, Ling YS, et al. The spectrum of viral pathogens in children with severe acute lower respiratory tract infection: A 3-year prospective study in the pediatric intensive care unit[J]. J Med Virol, 2019, 91(9): 1633-1642.
4 徐佳楠, 潘 明, 李天舒, 等. 多重PCR技术和呼吸道病原体微流体芯片在诊断儿童急性呼吸道病毒感染中的应用[J]. 中华实验和临床病毒学杂志, 2020, 34(2): 202-206.
5 Zhang N, Wang L, Deng X, et al. Recent advances in the detection of respiratory virus infection in humans[J]. J Med Virol, 2020, 92(4): 408-417.
6 Wilson P, Zumla A. Transmission and prevention of acute viral respiratory tract infections in hospitals[J]. Curr Opin Pulm Med, 2019, 25(3): 220-224.
7 Krantz EM, Zier J, Stohs E, et al. Antibiotic prescribing and respiratory viral testing for acute upper respiratory infections among adult patients at an ambulatory cancer center[J]. Clin Infect Dis, 2020, 70(7): 1421-1428.
8 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 中华医学会呼吸病学分会感染学组, 中华医学会《中华全科医师杂志》编辑委员会, 呼吸系统疾病基层诊疗指南编写专家组. 急性上呼吸道感染基层诊疗指南(2018年)[J]. 中华全科医师杂志, 2019, 18(5): 422-426.
9 张明新, 王 玫, 张韶娅, 等. 北京市某医院住院患者急性呼吸道感染病毒检测结果分析[J]. 中华医院感染学杂志, 2020, 30(18): 2754-2758.
10 Yen CY, Wu WT, Chang CY, et al. Viral etiologies of acute respiratory tract infections among hospitalized children-A comparison between single and multiple viral infections[J]. J Microbiol Immunol Infect, 2019, 52(6): 902-910.
11 Carlton HC, Savovic J, Dawson S, et al. Novel point-of-care biomarker combination tests to differentiate acute bacterial from viral respiratory tract infections to guide antibiotic prescribing: a systematic review[J]. Clin Microbiol Infect, 2021, 27(8): 1096-1108.
12 周 欣, 汤纯洁, 张燕玲. 急性上呼吸道感染患者病毒流行病学特征分析[J]. 公共卫生与预防医学, 2021, 32(1): 105-108.
13 王丽娜, 张 莹, 刘荣霞, 等. 康复新液联合重组人干扰素α-2b治疗宫颈炎疗效及对IL-6、TNF-α和VEGF水平影响[J]. 中华中医药学刊, 2020, 38(6): 186-189.
14 赵 倩, 张景丽, 程思思, 等. 重组人干扰素α-2b注射液雾化吸入与重组人干扰素α-2b喷雾剂局部外用喷咽部治疗手足口病的疗效[J]. 现代生物医学进展, 2019, 19(8): 1559-1562,1595.
15 杜春燕, 王春辉. 不同剂量重组人干扰素α2b注射液雾化吸入治疗小儿呼吸道合胞病毒肺炎疗效比较[J]. 陕西医学杂志, 2020, 49(1): 105-108.
16 孙一冉, 乔宝进. 重组人干扰素α-2b联合异丙托溴铵、头孢曲松治疗小儿支气管炎的临床效果及对miR-21、FOXP3表达的影响[J]. 临床医学研究与实践, 2023, 8(7): 83-85.
17 杜春燕, 王春辉. 不同剂量重组人干扰素α2b注射液雾化吸入治疗小儿呼吸道合胞病毒肺炎疗效比较[J]. 陕西医学杂志, 2020, 49(1): 105-108.
18 袁 茵, 彭 华. 重组人干扰素α-2b不同给药途径治疗婴幼儿毛细支气管炎的疗效及安全性[J]. 儿科药学杂志,2020, 26(9): 19-22.
19 田富香, 王栋梅, 徐峰峰. 重组人干扰素α-2b喷雾剂(假单胞菌)治疗儿童急性上呼吸道感染的临床疗效[J]. 生物医学工程与临床, 2020, 24(6): 748-751.
20 刘连凤, 史军然, 薛红霞, 等. 重组人干扰素α1b雾化吸入治疗儿童上呼吸道病毒感染及预防儿童上呼吸道病毒感染诱发毛细支气管炎效果研究[J]. 临床误诊误治, 2019, 32(5): 24-29.
21 吴建刚, 陈玉梅, 陈美元, 等. 哮喘患儿呼吸道病毒感染特征及其与α-干扰素治疗前后Th1、Th2细胞因子平衡的相关性研究[J]. 中国免疫学杂志, 2021, 37(15): 1877-1882.
22 王开梅, 林志雄, 胡祥英, 等. 呼吸道病毒感染对支气管哮喘患儿Th1/Th2细胞因子平衡的影响[J]. 中国医药导报, 2019, 16(5): 76-79.
23 周莲花, 刘 麟, 余庆乐, 等. 呼吸道合胞病毒下呼吸道感染患儿外周血miR-93-5p表达与Th1/Th2平衡的关系[J]. 河北医科大学学报, 2023, 44(7): 836-839,850.
24 邝向东, 刘 畅, 王成存, 等. Th1/Th2和Th17/Treg平衡与COPD合并下呼吸道感染的关系[J]. 中华医院感染学杂志, 2022, 32(3): 394-398.
25 麦朗君, 翟佳羽, 林烈桔, 等. 呼吸道合胞病毒下呼吸道感染患儿外周血miR-145表达及与Th1/Th2平衡的关系[J]. 河北医学, 2020, 26(8): 1277-1281.
26 周 婷, 丁 娴, 吴宏图, 等. 孟鲁司特钠联合重组人干扰素α-2b对呼吸道合胞病毒致毛细支气管炎患儿淋巴细胞Th1/Th2亚群的影响[J]. 药物评价研究, 2020, 43(4): 738-741.
27 邵远江,黄炳红. AECOPD患者感染呼吸道病毒特征及呼吸道合胞病毒感染与血清IP-10的关系[J]. 中国病原生物学杂志, 2021, 16(10): 1207-1210, 1215.
28 熊蕾蕾, 常会娟, 王 芳, 等. 雾化吸入不同剂量重组人干扰素α-2b治疗小儿病毒性肺炎效果分析[J]. 中国医学工程, 2020, 28(11): 57-60.
29 罗剑锋, 柏 涛. 重组人干扰素α-2b对慢性乙型肝炎患者T淋巴细胞免疫效应分子表达的影响[J]. 中国中西医结合消化杂志, 2018, 26(4): 328-331.
30 高淑林, 王 浩, 袁美锦. 重组人干扰素α-2b联合炎琥宁对手足口病患儿炎性反应和免疫功能的影响[J]. 河北医药, 2015, 37(18): 2732-2735.

备注/Memo

备注/Memo:

基金项目: 陕西省自然科学基础研究计划(2020JM-394)
通信作者: 陈冬丽, Email: 18992592618@163.com

常用功能

更新日期/Last Update: 2024-08-25